The Pharmacology Core's mission is to provide state-of-the-art bioanalytic technology and a broad range of pharmacology expertise to enable evaluation of critical pharmacological endpoints in clinical trials and preclinical studies. The Pharmacology Core is grouped in the Cross Disciplinary Research Core Cluster which, in addition to the Pharmacology Core, includes the Biostatistics, Genomics, and the Biobanking and Correlative Sciences Cores. Two services, Biospecimen Processing and Bioanalysis, are provided on a fee-for-service basis. Biospecimen Processing is a centralized resource for the acquisition, processing, and shipment of patient specimens (including blood and bone marrow samples) that are required for evaluation of pharmacokinetics or pharmacodynamics according to clinical protocol specifications to facilitate and support clinical and laboratory research. Bioanalysis provides development, validation and implementation of high-performance liquid chromatography (HPLC)-based analytical methods for quantitative measurement of drugs, metabolites, or endogenous compounds in biological samples (including biofluid, tissue and cell culture samples). In addition, a broad range of pharmacology support is provided, including: 1) pharmacokinetic study design; 2) pharmacokinetic data analysis and modeling using traditional compartmental and non-compartmental analysis, nonlinear mixed-effect (population) pharmacokinetic modeling, and physiologically based pharmacokinetic modeling; 3) in vitro drug metabolism studies; 4) metabolite identification; and 5) determination of drug plasma protein binding and plasma-to-blood ratio. The Core is equipped with state-of-the-art analytical instruments (such as the AB SCIEX QTRAP 6500 LC- MS/MS system) and pharmacokinetic analysis software. The laboratory is centrally located with convenient access for all KCI investigators. The services provided by the Pharmacology Core have contributed to 92 peer-reviewed publications during the current review period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-36
Application #
9384734
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
36
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642

Showing the most recent 10 out of 826 publications